

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Hemodynamics-Led Thrombolysis (HLT) allows Physicians to Personalize the Treatment of Blood Clots in the Lungs utilizing Real-Time Pulmonary Artery Pressure.

RICHMOND, VA, UNITED STATES, December 11, 2024 / EINPresswire.com/ -- [Liquet](https://www.liquetmedical.com/) Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its [Versus™ Catheter](https://www.liquetmedical.com/versus-catheter).



This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery pressure measurements, empowering clinicians to optimize treatment based on individual patient responses. This novel technology enables a new treatment category called “Hemodynamics-Led Thrombolysis (HLT).”

“

We believe this innovation has the potential to significantly improve patient outcomes, minimize risks, and reduce healthcare costs.”

John Schindler, CEO, Liquet Medical

“The Versus Catheter will allow for a more data-centric approach to each individual patient suffering from blood clots in their lungs,” said Luke Wilkins, MD, Interventional Radiologist at UVA Health. “Hemodynamic-led thrombolytic therapy is an opportunity to potentially improve patient outcomes, and we are looking forward to studying this device.”

Key Features and Benefits of the Versus™ Catheter:
Real-Time Pulmonary Artery Pressure Monitoring: Provides

physicians live data to assess patient hemodynamics before and during therapy to optimize

treatment decisions.

Dual-Tip Telescoping Catheter: Enables simultaneous treatment of both lungs with a single device, offering access site alternatives to the physician, and improving healthcare efficiency.

Flexible Placement: Standard guidewire technique or flow-directed balloon placement.

“FDA 510(k) clearance is a significant milestone for Liquet Medical and enables the commercial release of the Versus Catheter to hospitals and clinics across the U.S. We are thrilled to announce FDA clearance for the Versus™ Catheter, a groundbreaking advancement in the treatment of pulmonary artery blood clots,” said John Schindler, CEO of Liquet Medical. “We believe this innovation has the potential to significantly improve patient outcomes, minimize risks, and reduce healthcare costs.

About Liquet Medical

Liquet™ Medical is a forward-thinking medical device company focused on developing next-generation solutions for blood clots and other vascular conditions. Liquet Medical is dedicated to advancing healthcare through cutting-edge innovation with a patient-centric approach.

For media inquiries, please contact:

John Schindler, CEO Liquet Medical Inc.

(804) 690-9564

j.schindler@liquetmedical.com

www.liquetmedical.com

Liquet Medical, Inc
5619 County Hills Ln,
Glen Allen, VA 23059

Social Media Links:

<https://www.linkedin.com/company/liquet-medical-inc/>

<https://x.com/liquetmedical>

Angela Costello, Vice President of Communications
Virginia Innovation Partnership Corporation (VIPIC)
angela.costello@VirginalPC.org

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/768158971>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.